Connect With Us
Subscribe Now
Log In
Home
News
Education
Health
Tech
STEM
Advanced Manufacturing & Logistics
Life Sciences
Ag INnovation
INPower
Videos
Big Wigs
Submit Big Wigs
Events
Innovate Southwest Indiana â Evansville
Innovate West Central Indiana – Terre Haute
Innovate East Central – Muncie
Innovate Northeast Indiana – Fort Wayne
Newsletters
Podcasts
On-Air
TV & Radio Listings
Content Studio
Sponsored Content
Contact
About IIB
Meet the Team
Contact Us
Advertise
Gift Cards
Flagship Stations
Gerry’s Message
Speaking Engagement Request
Search
GO
Connect With Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
374.75
-0.75 (-0.20%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
64
65
Next >
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip?
↗
December 02, 2024
Via
The Motley Fool
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
↗
November 30, 2024
Via
The Motley Fool
Stock Market Hits Highs Despite Trump Tariff Threats, Nvidia, Tech Turkeys: Weekly Review
↗
November 29, 2024
The Nasdaq isn't at a high, but it isn't far off either.
Via
Investor's Business Daily
Topics
Government
Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?
↗
November 29, 2024
Via
The Motley Fool
2 Generic Drug Stocks Ready to Surge in 2025
November 27, 2024
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.
Via
MarketBeat
Topics
Government
Intellectual Property
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
↗
November 27, 2024
Via
The Motley Fool
Decoding Amgen's Options Activity: What's the Big Picture?
↗
November 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
November 26, 2024
Via
Benzinga
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
↗
November 26, 2024
The U.S. stock market traded mixed on Tuesday morning, with major indices showing tight movements as investors awaited the release of the Federal Reserve's November meeting minutes.
Via
Benzinga
Topics
Economy
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
↗
November 26, 2024
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.
Via
Benzinga
Amgen's Options Frenzy: What You Need to Know
↗
November 14, 2024
Via
Benzinga
What Analysts Are Saying About Amgen Stock
↗
November 14, 2024
Via
Benzinga
Pain In Retail
↗
November 26, 2024
It’s been a relatively busy morning for earnings, especially from retailers. Of the ten companies reporting, six topped EPS forecasts, seven beat sales forecasts, but two, Best Buy and Kohl’s lowered...
Via
Talk Markets
Topics
Stocks / Equities
Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test
↗
November 26, 2024
Over the course of a year, Amgen's MariTide helped patients lose about 20% of their body weight.
Via
Investor's Business Daily
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
↗
November 26, 2024
Amgen's Phase 2 MariTide trial showed ~20% weight loss at 52 weeks, cardiometabolic improvements, and no significant safety issues.
Via
Benzinga
Investing in Pharma Stocks? Check These 3 Things First
↗
November 22, 2024
Via
The Motley Fool
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
↗
November 22, 2024
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.
Via
Investor's Business Daily
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
↗
November 21, 2024
LLY stock struggles, falling 16.85% over the last month due to bearish technicals and political uncertainty. But with projected sales and earnings growth, could this be a buying opportunity?
Via
Benzinga
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
↗
November 19, 2024
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.
Via
Benzinga
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
November 18, 2024
Via
Benzinga
Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone
↗
November 18, 2024
Via
Benzinga
Topics
Stocks
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious
↗
November 16, 2024
Its future is bright, but that doesn't mean it'll always be smooth sailing.
Via
The Motley Fool
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
November 15, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
↗
November 15, 2024
This fund could be the perfect investment for those wanting financial freedom through endlessly growing dividends.
Via
The Motley Fool
2 Dividend Stocks to Buy Hand Over Fist in November
↗
November 14, 2024
These companies have solid businesses and excellent dividend growth track records.
Via
The Motley Fool
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
↗
November 13, 2024
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone density at the highest dose.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 13, 2024
Via
Benzinga
Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot
↗
November 13, 2024
Shares were rattled Tuesday after a report showed its obesity treatment can cause lower bone mineral density.
Via
Investor's Business Daily
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
↗
November 12, 2024
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC's Jim Cramer suggested the news could...
Via
Benzinga
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
↗
November 12, 2024
The company is testing MariTide as a monthly shot, rivaling weekly injections from Novo Nordisk and Eli Lilly.
Via
Investor's Business Daily
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
64
65
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
